Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Radiation Injuries 1Prostate Adenocarcinoma 1Lymphatic Metastasis 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

enzalutamide 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Biopsy 2relugolix 1luprolide acetate gel depot 1gallium 68 PSMA-11 1abiraterone 1X-Rays 1Radium-223 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation 1Prednisone 1Lymph Node Excision 1Glutamate Carboxypeptidase II 1Abiraterone Acetate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Prostate Adenocarcinoma × Lymph Node Excision × Clear all
NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Washington

Phase 2 Recruiting
100 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡